Azenta
AZTA Nasdaq· Life Sciences Tools & Services
Last close · Oct 23, 2026
$36.50
KIRA · Stoqly’s AI analyst, in plain words
- Azenta had $594M of revenue in fiscal 2025, up 3.6% on the year before. Over five years, revenue changed +8.9% a year on average.
- Its operating margin was −4.5%, up 4.4 pts: of every 100 in sales, about −5 is left after running the business.
- Azenta lost $55.8M in fiscal 2025.
- Free cash flow was $38.3M in fiscal 2025, 6.5% of revenue.
- Azenta returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 13.7%.
Market cap
$1.7B
P/E
—
Revenue
$594M
Net income
−$55.8M
Free cash flow
$38.3M
Operating margin
−4.5%
Azenta in 30 seconds · fiscal 2025
Are sales growing?
+3.6%
Only a little. Sales grew 3.6% last year.
Does it make a profit?
−9.4%
No. It lost money last year.
Does profit turn into cash?
6.5%
Partly. 6.5% of sales ends up as free cash.
What Azenta does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 4, 2025
- Legal name
- AZENTA, INC.
- CIK
- 0000933974
Azenta · AZTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $514M | $556M | $552M | $573M | $594M |
| Revenue growth | 32.2% | 8.1% | −0.7% | 4.0% | 3.6% |
| Gross margin | 47.5% | 46.0% | 43.4% | 44.4% | 45.5% |
| Operating margin | −6.1% | −4.5% | −11.1% | −8.9% | −4.5% |
| Net income | $111M | $2.1B | −$14.6M | −$165M | −$55.8M |
| Net margin | 21.6% | 384.0% | −2.7% | −28.8% | −9.4% |
| Diluted EPS | $1.49 | $28.48 | −$0.22 | −$3.10 | −$1.22 |
| Cash | |||||
| Cash from operations | $150M | −$466M | $5.8M | $49.7M | $72.2M |
| Capital expenditure | $52.8M | $73.4M | $39.4M | $37.4M | $33.9M |
| Free cash flow | $97.1M | −$539M | −$33.6M | $12.4M | $38.3M |
| FCF margin | 18.9% | −97.1% | −6.1% | 2.2% | 6.5% |
| Dividends paid | $29.7M | $7.5M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $839M | $662M | $0.0M |
| Share count change | 0.8% | 0.6% | −11.5% | −19.7% | −13.7% |
| Debt and strength | |||||
| Cash and short-term investments | $228M | $1.6B | $1.1B | $491M | $546M |
| Debt incl. finance leases | $50.0M | — | — | — | — |
| Shareholders' equity | $1.3B | $3.4B | $2.5B | $1.8B | $1.7B |
| Net debt / EBITDA | −5.2x | — | — | — | — |
| Current ratio | 2.3x | 10.7x | 6.7x | 4.0x | 3.0x |
| Interest coverage | −15.3x | −5.4x | — | — | — |
| Returns and quality | |||||
| Return on capital | −2.3% | — | — | — | — |
| Return on equity | 8.7% | 91.0% | −0.5% | −7.7% | −3.2% |
| Piotroski F-score | 7 | — | — | — | — |
| Altman Z'' | 3.4 | 15.4 | 12.0 | 9.7 | 9.1 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Azenta · AZTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Azenta AZTA | $1.7B | 3.6% | −4.5% | 6.5% | — | — | — |
| Bio-Techne TECH | $11.4B | −0.4% | 20.7% | 21.7% | 9.2% | — | 9 |
| Medpace MEDP | $19.2B | 20.0% | 21.1% | 27.0% | — | 37.6x | 4 |
| Bio-Rad Laboratories BIO | $10.0B | 0.7% | 1.8% | 14.5% | 0.5% | 46.6x | 5 |
| Waters WAT | $44.8B | 7.0% | 25.4% | 17.1% | 21.0% | — | 6 |
KIRA
At $36.50 a share, the company is worth $1.7B.
Azenta grew sales faster than 2 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000933974). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.